Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemia

被引:38
作者
Broxterman, HJ [1 ]
Lankelma, J [1 ]
Pinedo, HM [1 ]
Eekman, CA [1 ]
Wahrer, DCR [1 ]
Ossenkoppele, GJ [1 ]
Schuurhuis, GJ [1 ]
机构
[1] FREE UNIV AMSTERDAM HOSP,DEPT HEMATOL,NL-1007 MB AMSTERDAM,NETHERLANDS
关键词
P-glycoprotein; multidrug resistance; leukemia; PSC833; rhodamine; 123;
D O I
10.1038/sj.leu.2400685
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This paper summarizes experimental data and theoretical considerations, that are important for the measurement of P-glycoprotein (Pgp) function in acute myeloid leukemia (AML). The data are presented in subdivisions based on the techniques used, which will facilitate finding specific information. Based on our extensive experience with Pgp analysis, which includes radioactive assays, flow cytometry and fluorescence microscopy, we recommend a flow cytometry-based assay, that measures the effect of 2 mu M PSC 833 on rhodamine 123 (R123) accumulation as the most practical and sensitive functional Pgp test. In combination with the flow cytometric measurement of Pgp using an antibody against an extracellular epitope leg MRK16), this offers a sensitive and reproducible method for Pgp detection in AML, which is also rapid and practical. Furthermore, an R123 accumulation assay is specific for Pgp, because R123 is transported much less efficiently by the multidrug resistance protein (MRP) than by Pgp. Another probe of similar sensitivity and specificity is 3,3'-diethyloxacarbocyanine iodide. Alternatively, especially for the analysis of small numbers of cells (for example sorted subpopulations of leukemic cells), convenient and sensitive procedures are being developed by using DNA-binding Pgp substrates which remain fixed in the nuclei of the cells upon formaldehyde exposure for quantitative fluorescence laser scanning microscopy with image analysis, Less experimental data have been published to establish the optimal conditions for dual parameter flow cytometry (Pgp function, in eg Pgp(+) or CD34(+) cells). However, laboratories with flow cytometry experience will be able to implement this useful option to analyze subpopulations of cells.
引用
收藏
页码:1110 / 1118
页数:9
相关论文
共 48 条
  • [1] ISOLATION AND GENETIC-CHARACTERIZATION OF HUMAN KB-CELL LINES RESISTANT TO MULTIPLE-DRUGS
    AKIYAMA, SI
    FOJO, A
    HANOVER, JA
    PASTAN, I
    GOTTESMAN, MM
    [J]. SOMATIC CELL AND MOLECULAR GENETICS, 1985, 11 (02) : 117 - 126
  • [2] ArchinalMattheis A, 1995, ONCOL RES, V7, P603
  • [3] Beck WT, 1996, CANCER RES, V56, P3010
  • [4] CORRELATION BETWEEN FUNCTIONAL AND MOLECULAR ANALYSIS OF MDR1 P-GLYCOPROTEIN IN HUMAN SOLID-TUMOR XENOGRAFTS
    BROXTERMAN, HJ
    FELLER, N
    KUIPER, CM
    BOVEN, E
    VERSANTVOORT, CHM
    TEERLINK, T
    PINEDO, HM
    LANKELMA, J
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 61 (06) : 880 - 886
  • [5] DAUNOMYCIN ACCUMULATION IN RESISTANT TUMOR-CELLS AS A SCREENING MODEL FOR RESISTANCE MODIFYING DRUGS - ROLE OF PROTEIN-BINDING
    BROXTERMAN, HJ
    KUIPER, CM
    SCHUURHUIS, GJ
    VANDERHOEVEN, JJM
    PINEDO, HM
    LANKELMA, J
    [J]. CANCER LETTERS, 1987, 35 (01) : 87 - 95
  • [6] Quality control of multidrug resistance assays in adult acute leukemia: Correlation between assays for P-glycoprotein expression and activity
    Broxterman, HJ
    Sonneveld, P
    Feller, N
    Ossenkoppele, GJ
    Wahrer, DCR
    Eekman, CA
    Schoester, M
    Lankelma, J
    Pinedo, HM
    Lowenberg, B
    Schuurhuis, GJ
    [J]. BLOOD, 1996, 87 (11) : 4809 - 4816
  • [7] INCREASE OF DAUNORUBICIN AND VINCRISTINE ACCUMULATION IN MULTIDRUG RESISTANT HUMAN OVARIAN-CARCINOMA CELLS BY A MONOCLONAL-ANTIBODY REACTING WITH P-GLYCOPROTEIN
    BROXTERMAN, HJ
    KUIPER, CM
    SCHUURHUIS, GJ
    TSURUO, T
    PINEDO, HM
    LANKELMA, J
    [J]. BIOCHEMICAL PHARMACOLOGY, 1988, 37 (12) : 2389 - 2393
  • [8] How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein
    Broxterman, HJ
    Lankelma, J
    Pinedo, HM
    [J]. EUROPEAN JOURNAL OF CANCER, 1996, 32A (06) : 1024 - 1033
  • [9] BROXTERMAN HJ, 1997, IN PRESS BR J CANC
  • [10] BROXTERMAN HJ, 1995, DRUG TRANSPORT ANTIM, P21